MTOR and melanoma: These results suggest that the use of pan-mTOR inhibitors, often proposed in the context of melanoma treatment [40, 49], could potentially represent a double-edged sword, with mTORC1 inhibition potentially counteracting therapeutic resistance while mTORC2 inhibition exacerbating it.